ZAZNĚLO NA XXXVII. sjezdu českých a slovenských alergologů a klinických imunologů – On-line: 8.–9. 10. 2020

58 SOLEN www.solen.cz ZAZNĚLO NA XXXVII. SJEZDU ČESKÝCH A SLOVENSKÝCH ALERGOLOGŮ A KLINICKÝCH IMUNOLOGŮ 4. Jolles S, Chapel H, Litzman J. When to initiate immuno- globulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017 Jun;188(3):333– 341. doi: 10.1111/cei.12915. Epub 2017 Jan 30. PMID: 28000208; PMCID: PMC5422851. 5. Guideline on core SmPC for human normal immunoglobu- lin for intravenous administration (IVIg); 28 June 2018 EMA/ CHMP/BPWP/94038/2007 Rev. 5 Committee for Medicinal Products for Human Use (CHMP). 6. Guideline on the clinical investigation of human nor- mal immunoglobulin for subcutaneous and/or intra- muscular administration (SCIg/IMIg); 23 July 2015 EMA/ CHMP/BPWP/410415/2011 rev 1 Committee for Medici- nal Products for Human Use (CHMP) https://www.ema. europa.eu/en/documents/scientific‑guideline/guideline­ ‑clinical‑investigation‑human‑normal‑immunoglobulin­ ‑subcutaneous/intramuscular‑administration‑scig/imig_ en.pdf. 7. Hanitsch L, Baumann U, Boztug K, Burkhard‑Meier U, Fasshauer M, Habermehl P, Hauck F, Klock G, Liese J, Mey- er O, Müller R, Pachlopnik‑Schmid J, Pfeiffer‑Kascha D, Warnatz K, Wehr C, Wittke K, Niehues T, von Bernuth H. Treatment and management of primary antibody deficiency: German inter- disciplinary evidence‑based consensus guideline. Eur J Immu- nol. 2020 Oct; 50(10): 1432–1446. doi: 10.1002/eji.202048713. Epub 2020 Sep 9. PMID: 32845010. 8. Sánchez‑Ramón S, de Gracia J, García‑Alonso AM, Rodrí- guez Molina JJ, Melero J, de Andrés A, García Ruiz de Mora- les JM, Ferreira A, Ocejo‑Vinyals JG, Cid JJ, García Martínez JM, Lasheras T, Vargas ML, Gil‑Herrera J, García Rodríguez MC, Castañer JL, González Granado LI, Allende LM, Soler­ ‑Palacin P, Herráiz L, López Hoyos M, Bellón JM, Silva G, Gur- bindo DM, Carbone J, Rodríguez‑Sáinz C, Matamoros N, Par- ker AR, Fernández‑Cruz E; EMPATHY group. Multicenter stu- dy for the evaluation of the antibody response against sal- monella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti‑polysaccharide antibody production deficiency in pa- tients with primary immunodeficiency. Clin Immunol. 2016 Aug;169: 80–84. doi: 10.1016/j.clim.2016. 05. 006. Epub 2016 May 25. PMID: 27236002. 9. Driessen GJ, Dalm VA, van Hagen PM, Grashoff HA, Hartwig NG, van Rossum AM, Warris A, de Vries E, Barendregt BH, Pico I, Posthumus S, van ZelmMC, van Dongen JJ, van der Burg M. Common variable immunodeficiency and idiopathic prima- ry hypogammaglobulinemia: two different conditions within the same disease spectrum. Haematologica. 2013 Oct; 98(10): 1617–1623. doi: 10.3324/haematol.2013.085076. Epub 2013 Jun 10. PMID: 23753020; PMCID: PMC3789468. 10. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune defi- ciency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Im- munol. 2013 Nov; 174(2): 203–211. doi: 10.1111/cei.12178. PMID: 23859429; PMCID: PMC3828823. 11. Wolf HM, Thon V, Litzman J, Eibl MM. Detection of impai- red IgG antibody formation facilitates the decision on ear- ly immunoglobulin replacement in hypogammaglobuline- mic patients. Front Immunol. 2015 Feb 2; 6: 32. doi: 10.3389/ fimmu.2015.00032. PMID: 25699049; PMCID: PMC4313720. 12. Ameratunga R, Ahn Y, Steele R, Woon ST. The Natural His- tory of Untreated Primary Hypogammaglobulinemia in Adul- ts: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID). Front Immunol. 2019 Jul 17; 10: 1541. doi: 10.3389/fimmu.2019.01541. PMID: 31379811; PMCID: PMC6652801. 13. Patel SY, Carbone J, Jolles S. The Expanding Field of Se- condary Antibody Deficiency: Causes, Diagnosis, and Man- agement. Front Immunol. 2019 Feb 8; 10: 33. doi: 10.3389/ fimmu.2019.00033. PMID: 30800120; PMCID: PMC6376447. 14. Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan‑Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Hypogamma- globulinemia in newly diagnosed chronic lymphocytic leu- kemia: Natural history, clinical correlates, and outcomes. Ca- ncer. 2015 Sep 1; 121(17): 2883–2891. doi: 10.1002/cncr.29438. Epub 2015 Apr 30. PMID: 25931291; PMCID: PMC4545721. 15. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2): 240–9. doi: 10.1053/j.seminoncol.2005. 12. 013. PMID: 16616071. 16. Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary immunodeficiency in lymphoproli- ferative malignancies. Hematol Oncol. 2016 Sep; 34(3): 121– 32. doi: 10.1002/hon.2323. Epub 2016 Jul 12. PMID: 27402426. 17. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low‑grade B‑cell tumors. Blood. 1989 Feb; 73(2): 366–368. PMID: 2492832. 18. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, Gale RP, Chapel HM, Bunch C, Rai KR, Foon K, Courter SG, Tait D. Intravenous immu- noglobulin for the prevention of infection in chronic lym- phocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988 Oct 6; 319(14): 902–907. doi: 10.1056/ NEJM198810063191403. PMID: 2901668. 19. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2): 240–249. doi: 10.1053/j.seminoncol.2005. 12. 013. PMID: 16616071. 20. Sklenar I, Schiffman G, Jønsson V, Verhoef G, Birgens H, Boogaerts M, Ferrant A, Christensen BE, Hasle H, Drivsholm A, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in pa- tients with chronic lymphocytic leukaemia and multiple myeloma. Oncology. 1993 Nov–Dec; 50(6): 466–477. doi: 10.1159/000227231. PMID: 8233289. 21. Jurlander J, Geisler CH, Hansen MM. Treatment of hypo- gammaglobulinaemia in chronic lymphocytic leukaemia by low‑dose intravenous gammaglobulin. Eur J Haematol. 1994 Aug; 53(2): 114–118. doi: 10.1111/j.1600-0609.1994.tb01874.x. PMID: 8088382. 22. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Associa- tion of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018 Nov 2; 1(7): e184169. doi: 10.1001/jamanetworko- pen.2018.4169. PMID: 30646343; PMCID: PMC6324375. 23. Patel V, Cowan J. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency. Expert Rev Clin Immunol. 2020 Jul; 16(7): 711– 716. doi: 10.1080/1744666X.2020.1788939. Epub 2020 Jul 7. PMID: 32588670. 24. Johnston SL, Hollingsworth R. Immunoglobulin thera- py. Clin Med (Lond). 2016 Dec; 16(6): 576–579. doi: 10.7861/ clinmedicine.16-6-576. PMID: 27927824; PMCID: PMC6297324. 25. Litzman: Léčba humorálních imunodeficiencí. Vnitřní lé- kařství 2019; 65(2): 126–130. 26. Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutane- ous administration using recombinant human hyaluro- nidase PH20. Drug Deliv. 2019 Dec; 26(1): 98–106. doi: 10.1080/10717544.2018.1551442. Erratum in: Drug Deliv. 2019 Mar 25:1. PMID: 30744432; PMCID: PMC6394283. 27. Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D. Long‑Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase‑Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficien- cy. J Clin Immunol. 2016 Aug; 36(6): 571–582. doi: 10.1007/ s10875-016-0298-x. Epub 2016 May 25. PMID: 27220317; PM- CID: PMC4940441. 28. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase‑facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Aller- gy Clin Immunol. 2012 Oct; 130(4): 951–7.e11. doi: 10.1016/j. jaci.2012. 06. 021. Epub 2012 Jul 28. PMID: 22846381. 29. Ponsford M, Carne E, Kingdon C, Joyce C, Price C, Williams C, El‑Shanawany T, Williams P, Jolles S. Facilitated subcuta- neous immunoglobulin (fSCIg) therapy--practical conside- rations. Clin Exp Immunol. 2015 Dec; 182(3): 302–313. doi: 10.1111/cei.12694. Epub 2015 Sep 22. PMID: 26288095; PM- CID: PMC4636892. 30. Souhrn údajů o přípravku HyQvia 31. Cruz RJ, Dasso JF, Duff C, Krasnopero D, Long Z, Elli- son M, Nieves D, Sriaroon P, Asante‑Korang A, Walter JE. Hyaluronidase‑Facilitated High‑Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T‑Cell Lymphope- nia. Open Forum Infect, DiS. 2020 Mar 12; 7(5): ofaa076. doi: 10.1093/ofid/ofaa076. PMID: 32391400; PMCID: PMC7200086. 32. Speth F, Haas JP, Hinze CH. Treatment with high‑dose re- combinant human hyaluronidase‑facilitated subcutaneous immune globulins in patients with juvenile dermatomyo- sitis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol Online J. 2016 Sep 13; 14(1): 52. doi: 10.1186/s12969-016-0112-6. PMID: 27623619; PMCID: PMC5022227. 33. Jolles S. Hyaluronidase facilitated subcutaneous immu- noglobulin in primary immunodeficiency. Immunotargets Ther. 2013 Sep 18;2:125–33. doi: 10.2147/ITT.S31136. PMID: 27471693; PMCID: PMC4928364. 34. Údaje z národního registru PID 35. Maurer M, Magerl M, Ansotegui I, Aygören‑Pürsün E, Bet- schel S, Bork K, Bowen T, Balle Boysen H, Farkas H, Grumach AS, Hide M, Katelaris C, Lockey R, Longhurst H, Lumry WR, Martinez‑Saguer I, Moldovan D, Nast A, Pawankar R, Potter P, Riedl M, Ritchie B, Rosenwasser L, Sánchez‑Borges M, Zhi Y, Zuraw B, Craig T. The international WAO/EAACI guideline for the management of hereditary angioedema‑The 2017 re- vision and update. Allergy. 2018 Aug; 73(8): 1575–1596. doi: 10.1111/all.13384. Epub 2018 Mar 12. PMID: 29318628. 36. Betschel S, Badiou J, Binkley K, Borici‑Mazi R, Hébert J, Kanani A, Keith P, Lacuesta G, Waserman S, Yang B, Aygören­ ‑Pürsün E, Bernstein J, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Grumach A, Katelaris C, Longhurst H, Riedl M, Zu- raw B, Berger M, Boursiquot JN, Boysen H, Castaldo A, Cha- pdelaine H, Connors L, Fu L, Goodyear D, Haynes A, Kamra P, Kim H, Lang‑Robertson K, Leith E, McCusker C, Moote B, O‘Keefe A, Othman I, Poon MC, Ritchie B, St‑Pierre C, Stark D, Tsai E. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019 Nov 25; 15: 72. doi: 10.1186/s13223-019-0376-8. Erratum in: Allergy Ast- hma Clin Immunol. 2020 May 6; 16: 33. PMID: 31788005; PM- CID: PMC6878678. 37. Souhrn údajů o přípravku Takhzyro. Dostupné na: www. takeda.com/4ab56f/siteassets/cs‑cz/home/what‑we‑do/pro- ducts/vpois/takhzyro‑spc-2020-07.pdf 38. Zuraw BL. The pathophysiology of hereditary angioe- dema. World Allergy Organ J. 2010 Sep; 3(9 Suppl): S25–28. doi: 10.1097/WOX.0b013e3181f3f21c. PMID: 23282866; PM- CID: PMC3666152. 39. Caccia S, Suffritti C, Cicardi M. Pathophysiology of He- reditary Angioedema. Pediatr Allergy Immunol Pulmonol. 2014 Dec 1; 27(4):159–163. doi: 10.1089/ped.2014.0425. PMID: 25538858; PMCID: PMC4268578. 40. Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhu- rst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez­ ‑Saguer I, Davis‑Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza‑Urdaz RH, Gi- erer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, Maurer M; HELP Investigators. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018 Nov 27; 320(20): 2108– 2121. doi: 10.1001/jama.2018.16773. Erratum in: JAMA. 2019 Apr 23;321(16):1636. PMID: 30480729; PMCID: PMC6583584.